Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | PDE9A | O76083 | 4/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.39 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15997907 | 0.85 | CYP11B2 (0.50) | KDM4EPDE9ASCN9ASCN10AALDH1A1 | |
| SCHEMBL22499128 | 0.83 | RXRA (0.47) | KDM4EALDH1A1CAMKK1CAMKK2 | |
| SCHEMBL22499127 | 0.83 | RXRA (0.47) | KDM4EALDH1A1CAMKK1CAMKK2 | |
| SCHEMBL31179070 | 0.83 | RXRA (0.47) | KDM4EALDH1A1CAMKK1CAMKK2 | |
| SCHEMBL3465105 | 0.80 | KDM4E (0.42) | KDM4EPDE9ASCN9ASCN10AKDM5A | |
| SCHEMBL2594585 | 0.79 | OPRK1 (0.43) | KDM4EPDE9AKDM5AKDM4CKDM5B | |
| SCHEMBL2591384 | 0.79 | PDE9A (0.43) | KDM4EPDE9AKDM5AKDM4CKDM5B | |
| SCHEMBL20162102 | 0.77 | PDE9A (0.41) | KDM4EPDE9AKDM5AKDM4CKDM5B | |
| SCHEMBL19048628 | 0.76 | PDE9A (0.47) | PDE9ASCN9ASCN10APDE1CKMT2A | |
| SCHEMBL4108821 | 0.76 | PDE9A (0.43) | PDE9ASCN9ASCN10APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2772484-B1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-06-28 | — | — | EP | disclosed |
| US-9266840-B2 | Bicyclic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-02-23 | — | — | US | disclosed |
| US-9266840-B2 | Bicyclic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-02-23 | — | — | US | disclosed |
| US-20140249151-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20140249151-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-09-04 | — | — | US | disclosed |
| EP-2772484-A1 | BICYCLIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2681216-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| EP-2566328-A1 | INDAZOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2012118812-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2012-09-07 | — | — | WO | disclosed |
| WO-2011140325-A1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249151-A1 | BICYCLIC HETEROCYCLIC COMPOUND | HSD11B1, HSD17B11, HSD17B1 | KDM4E 3611/4885PDE9A 2315/4885SCN9A 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.